Acute-phase responses in transgenic mice with CNS overexpression of IL-1 receptor antagonist

1  Department of Neurochemistry and Neurotoxicology, Arrhenius Laboratories for Natural Sciences, Stockholm University, S-106 91 Stockholm; and 2  Division of Geriatric Medicine, Department of Clinical Neuroscience and Family Medicine, Novum, S-141 86 Huddinge, Sweden The interleukin-1 (IL-1) recept...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of physiology. Regulatory, integrative and comparative physiology Vol. 276; no. 3; pp. 644 - R651
Main Authors Lundkvist, Johan, Sundgren-Andersson, Anna K, Tingsborg, Susanne, Ostlund, Pernilla, Engfors, Catherine, Alheim, Katarina, Bartfai, Tamas, Iverfeldt, Kerstin, Schultzberg, Marianne
Format Journal Article
LanguageEnglish
Published United States 01.03.1999
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:1  Department of Neurochemistry and Neurotoxicology, Arrhenius Laboratories for Natural Sciences, Stockholm University, S-106 91 Stockholm; and 2  Division of Geriatric Medicine, Department of Clinical Neuroscience and Family Medicine, Novum, S-141 86 Huddinge, Sweden The interleukin-1 (IL-1) receptor antagonist (IL-1ra) is an endogenous antagonist that blocks the effects of the proinflammatory cytokines IL-1 and IL-1 by occupying the type I IL-1 receptor. Here we describe transgenic mice with astrocyte-directed overexpression of the human secreted IL-1ra (hsIL-1ra) under the control of the murine glial fibrillary acidic protein (GFAP) promoter. Two GFAP-hsIL-1ra strains have been generated and characterized further: GILRA2 and GILRA4. These strains show a brain-specific expression of the hsIL-1ra at the mRNA and protein levels. The hsIL-1ra protein was approximated to ~50 ng/brain in cytosolic fractions of whole brain homogenates, with no differences between male and female mice or between the two strains. Furthermore, the protein is secreted, inasmuch as the concentration of hsIL-1ra in the cerebrospinal fluid was 13 (GILRA2) to 28 (GILRA4) times higher in the transgenic mice than in the control animals. To characterize the transgenic phenotype, GILRA mice and nontransgenic controls were injected with recombinant human IL-1 (central injection) or lipopolysaccharide (LPS, peripheral injection). The febrile response elicited by IL-1 (50 ng/mouse icv) was abolished in hsIL-1ra-overexpressing animals, suggesting that the central IL-1 receptors were occupied by antagonist. The peripheral LPS injection (25 µg/kg ip) triggered a fever in overexpressing and control animals. Moreover, no differences were found in LPS-induced (100 and 1,000 µg/kg ip; 1 and 6 h after injection) IL-1 and IL-6 serum levels between GILRA and wild-type mice. On the basis of these results, we suggest that binding of central IL-1 to central IL-1 receptors is not important in LPS-induced fever or LPS-induced IL-1 and IL-6 plasma levels. glial fibrillary acidic protein promoter; lipopolysaccharide; interleukin-1; cytokine
ISSN:0363-6119
0002-9513
1522-1490
DOI:10.1152/ajpregu.1999.276.3.R644